Petros Pharmaceuticals, Inc. Stock-Based Compensation
Petros Pharmaceuticals, Inc. (PTPI) reported Stock-Based Compensation of $238.22 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Petros Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $117.91K, a 58.64% increase year-over-year.
- Petros Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $120.32K, a 50.33% increase year-over-year.
- Petros Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-06-30 was $74.32K.
- Petros Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-03-31 was $80.04K.
- Petros Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $304.63K, a 54.47% increase from fiscal 2024.
- Petros Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $197.22K, a 52.73% decline from fiscal 2023.
- Petros Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $417.23K, a 65.09% decline from fiscal 2022.
- Petros Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $1.20M, a 8.43% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $117.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $238.22K 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | $120.32K 10-Q · filed 2026-05-13 | |||||
| 2025-12-31 | $304.63K 10-K · filed 2026-04-15 | |||||
| 2025-06-30 | $74.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $154.36K 10-Q · filed 2026-08-13 | ||||
| 2025-03-31 | $80.04K 10-Q · filed 2026-05-13 | |||||
| 2024-12-31 | $197.22K 10-K · filed 2026-04-15 | |||||
| 2023-12-31 | $212.74K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $243.58K derived: sum of 2 quarters · filed 2025-03-31 | $286.89K derived: sum of 3 quarters · filed 2025-03-31 | $417.23K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $30.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | $74.16K derived: sum of 2 quarters · filed 2023-11-15 | $204.49K 10-Q · filed 2023-11-15 | $433.34K derived: sum of 4 quarters · filed 2024-04-01 | ||
| 2023-06-30 | $43.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $173.65K 10-Q · filed 2023-08-14 | $402.50K derived: sum of 3 quarters · filed 2024-04-01 | $710.63K derived: sum of 4 quarters · filed 2024-04-01 | ||
| 2023-03-31 | $130.34K 10-Q · filed 2023-05-15 | $359.18K derived: sum of 2 quarters · filed 2024-04-01 | $667.32K derived: sum of 3 quarters · filed 2024-04-01 | $969.58K derived: sum of 4 quarters · filed 2024-04-01 | ||
| 2022-12-31 | $228.84K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $536.98K derived: sum of 2 quarters · filed 2024-04-01 | $839.25K derived: sum of 3 quarters · filed 2024-04-01 | $1.20M 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $308.14K 10-Q/A · filed 2022-11-15 | $610.40K derived: sum of 2 quarters · filed 2022-11-15 | $966.23K 10-Q · filed 2023-11-15 | $1.09M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2022-06-30 | $302.26K 10-Q · filed 2022-08-12 | $658.09K 10-Q · filed 2023-08-14 | $784.57K derived: sum of 3 quarters · filed 2023-05-15 | $837.73K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2022-03-31 | $355.83K 10-Q · filed 2023-05-15 | $482.30K derived: sum of 2 quarters · filed 2023-05-15 | $535.47K derived: sum of 3 quarters · filed 2023-05-15 | $1.13M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $126.47K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | $179.64K derived: sum of 2 quarters · filed 2023-03-31 | $770.14K derived: sum of 3 quarters · filed 2023-03-31 | $1.31M 10-K · filed 2023-03-31 | $1.12M 10-K · filed 2022-03-31 | |
| 2021-09-30 | $53.17K 10-Q/A · filed 2022-11-15 | $643.67K derived: sum of 2 quarters · filed 2022-11-15 | $1.18M 10-Q/A · filed 2022-11-15 | $990.88K 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | $590.50K 10-Q · filed 2022-08-12 | $937.71K 10-Q · filed 2022-08-12 | ||||
| 2021-03-31 | $347.21K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |